PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Successful coronary stenting in a patient with factor V deficiency in the absence of fresh frozen plasma transfusion: Case report.

Abstract Drug-eluting stent (DES) implantation in a patient with factor V deficiency (F5D) is very complex. No antithrombotic therapy study has been reported for F5D patients who undergo a coronary stenting procedure.
PMID
Related Publications

Design and Rationale of the RE-DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fibrillation Who Have Undergone Percutaneous Coronary Intervention With Stenting.

Platelet Reactivity and Clinical Outcomes After Coronary Artery Implantation of Drug-Eluting Stents in Subjects With Peripheral Arterial Disease: Analysis From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents).

Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial.

Ticagrelor. Acute coronary syndromes: nothing new.

Long-term ticagrelor monotherapy versus standard dual antiplatelet therapy followed by aspirin monotherapy in patients undergoing biolimus-eluting stent implantation: rationale and design of the GLOBAL LEADERS trial.

Authors

Mayor MeshTerms

Drug-Eluting Stents

Keywords
Journal Title medicine
Publication Year Start




PMID- 29390379
OWN - NLM
STAT- MEDLINE
DCOM- 20180212
LR  - 20180212
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 96
IP  - 50
DP  - 2017 Dec
TI  - Successful coronary stenting in a patient with factor V deficiency in the absence
      of fresh frozen plasma transfusion: Case report.
PG  - e9274
LID - 10.1097/MD.0000000000009274 [doi]
AB  - RATIONALE: Drug-eluting stent (DES) implantation in a patient with factor V
      deficiency (F5D) is very complex. No antithrombotic therapy study has been
      reported for F5D patients who undergo a coronary stenting procedure. PATIENT
      CONCERNS: A 73-year-old woman presented with chest discomfort and exertional
      dyspnea. Coronary stenting was performed successfully using DES stents.
      DIAGNOSES: The D-dimer, prothrombin time, and partial thromboplastin time
      prolongation persisted from admission until 24 hours after coronary stenting.
      Epistaxis and blood-tinged sputum occurred on day 3. The antiplatelet therapy
      measured using a Multiplate Analyzer was adequate, and other laboratory findings 
      except factor V activity (14%) were within normal ranges; she was diagnosed with 
      F5D based on low factor V activity. INTERVENTIONS: While taking 90 mg of
      ticagrelor and 100 mg of aspirin daily, the patient revisited due to recurrent
      epistaxis, hemoptysis, and coughing on day 26. Epistaxis and hemoptysis stopped
      after the aspirin was discontinued. Finally, the daily maintenance dose was
      reduced to 90 mg of ticagrelor once. OUTCOMES: She led healthy life for 9 months 
      without any recurrent symptoms and the test results also were stabilized.
      LESSONS: We report a case of an F5D patient who underwent coronary stenting in
      the absence of frozen fresh plasma transfusion who received successful
      maintenance therapy using a single antiplatelet agent (90 mg of ticagrelor/day)
      with recurrent multiple mucosal bleeding events after coronary stenting.
CI  - Copyright (c) 2017 The Authors. Published by Wolters Kluwer Health, Inc. All
      rights reserved.
FAU - Choi, Seongil
AU  - Choi S
FAU - Song, MooKon
AU  - Song M
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Purinergic P2Y Receptor Antagonists)
RN  - GLH0314RVC (Ticagrelor)
RN  - K72T3FS567 (Adenosine)
SB  - AIM
SB  - IM
MH  - Adenosine/*analogs & derivatives/therapeutic use
MH  - Aged
MH  - Blood Coagulation Tests
MH  - Coronary Stenosis/diagnosis/*drug therapy
MH  - *Drug-Eluting Stents
MH  - Factor V Deficiency/*complications
MH  - Female
MH  - Humans
MH  - Purinergic P2Y Receptor Antagonists/*therapeutic use
EDAT- 2018/02/03 06:00
MHDA- 2018/02/13 06:00
CRDT- 2018/02/03 06:00
PHST- 2018/02/03 06:00 [entrez]
PHST- 2018/02/03 06:00 [pubmed]
PHST- 2018/02/13 06:00 [medline]
AID - 10.1097/MD.0000000000009274 [doi]
AID - 00005792-201712150-00129 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2017 Dec;96(50):e9274. doi: 10.1097/MD.0000000000009274.